Growth differentiation factor (GDF)-15 and soluble ST2 (sST2) are established prognostic markers in acute and chronic heart failure. Assessment of these biomarkers might improve arrhythmic risk stratification of patients with non-ischaemic, dilated cardiomyopathy (DCM) based on left ventricular ejection fraction (LVEF). We studied the prognostic value of GDF-15 and sST2 for prediction of arrhythmic death (AD) and all-cause mortality in patients with DCM. We prospectively enrolled 52 patients with DCM and LVEF ≤ 50%. Primary end-points were time to AD or resuscitated cardiac arrest (RCA), and secondary end-point was all-cause mortality. The median follow-up time was 7 years. A cardiac death was observed in 20 patients, where 10 patients had an AD and 2 patients had a RCA. One patient died a noncardiac death. GDF-15, but not sST2, was associated with increased risk of the AD/ RCA with a hazard ratio (HR) of 2.1 (95% CI = 1.1-4.3; P = .031). GDF-15 remained an independent predictor of AD/RCA after adjustment for LVEF with adjusted HR of 2.2 (95% CI = 1.1-4.5; P = .028). Both GDF-15 and sST2 were independent predictors of all-cause mortality (adjusted HR = 2.4; 95% CI = 1.4-4.2; P = .003 vs HR = 1.6; 95% CI = 1.05-2.7; P = .030). In a model including GDF-15, sST2, LVEF and NYHA functional class, only GDF-15 was significantly associated with the secondary end-point (adjusted HR = 2.2; 95% CI = 1.05-5.2; P = .038). GDF-15 is superior to sST2 in prediction of fatal arrhythmic events and all-cause mortality in DCM. Assessment of GDF-15 could provide additional information on top of LVEF and help identifying patients at risk of arrhythmic death.
primary prevention with implantable cardioverter defibrillators (ICD) are based on the degree of LV ejection fraction (LVEF ≤ 30%-40%) reduction. 3, 4 However, patients with ischaemic heart disease seem to have more benefit from prophylactic ICD implantation. [5] [6] [7] Furthermore, the recently published DANISH trial has demonstrated no mortality benefit from prophylactic ICD implantation in non-ischaemic DCM. 8 Although LVEF is currently the best marker for risk stratification, it lacks specificity and many DCM patients with ICDs never receive appropriate therapies. 9, 10 It is well known that VT also occurs in patients with borderline or mildly reduced LVEF. 3 Noninvasive testing and LVEF could not reliably identify patients with DCM at risk of fatal VTs. 11 Therefore, the identification of additional markers for arrhythmia risk stratification of patients with DCM is essential.
Growth differentiation factor (GDF)-15 and soluble ST2 (sST2)
are well-established prognostic markers for mortality in acute and chronic heart failure [12] [13] [14] [15] [16] [17] as well as in acute myocardial infarction. 18 Inflammation and myocardial fibrosis, with subsequent ventricular remodelling and impairment of systolic function, are important pathophysiological mechanisms for VTs in patients with DCM. 19, 20 Both GDF-15 and sST2 show strong correlations with myocardial stress and fibrosis, [21] [22] [23] and have been associated with sudden cardiac death in DCM. 24, 25 The aim of the study was a head-to-head comparison of GDF-15
and sST2 for prediction of arrhythmic death (AD) and all-cause mortality in patients with non-ischaemic DCM.
| MATERIALS AND METHODS

| Study participants
This was a prospective, longitudinal cohort study. A total of 52 consecutive patients with non-ischaemic DCM were included in the study in 2002 and 2003 at the Medical University of Vienna, Austria. Patients were eligible to participate if they were aged ≥18 years, had a LVEF of ≤50%, had recently undergone coronary angiography with ventriculography as standard use of care independently from study participation, echocardiography, MRI at the physician's discretion, had no history of sustained ventricular arrhythmia or permanent atrial fibrillation and were not dependent on ventricular pacing. Ambulatory ECG, Holter recordings and exercise tests were performed at baseline in all patients. New York Heart Association (NYHA) classification was documented for each patient at the baseline according to ESC and AHA Heart Failure Guidelines: NYHA Class I: no limitation of physical activity; NYHA Class II: slight limitation of physical activity in which ordinary physical activity leads to fatigue, palpitation, dyspnoea, or anginal pain; the person is comfortable at rest; Class III: marked limitation of physical activity in which less-than-ordinary activity results in fatigue, palpitation, dyspnoea, or anginal pain; the person is comfortable at rest; Class IV: inability to carry on any physical activity without discomfort but also symptoms of heart failure or the anginal syndrome even at rest, with increased discomfort if any physical activity is undertaken. 4, 26 Patients were followed up between 2003 and 2013. The study was approved by the local ethics committee, and all participants gave written informed consent. 
| Biomarker measurements
| End-points
The primary end-point was time to AD or resuscitated cardiac arrest (RCA). All-cause mortality was the secondary end-point. Deaths were
categorized using an adapted form of the Hinkle classification. 33 Appropriate ICD therapy without VT acceleration that failed to save the patient's life at the time of arrhythmias was classified as AD. 34 An RCA was ventricular fibrillation or VT > 240 beats per minute leading to syncope before ICD therapy, and multiple slower VT episodes (electrical storm) leading to syncope and ICD discharge without ICD therapy-related acceleration. All other ICD therapies because of VT < 240 beats per minute were not taken as surrogate for AD. Study end-point data were collected through pre-planned ambulatory visits. In case of non-appearance study, end-point data were collected through treating physicians or patients 0 relatives, and in case of death through abduction, which is mandatory in Austria.
| Statistical analysis
Categorical variables are summarized as counts and percentages and are compared by the v 3 | RESULTS No patients were lost during follow-up. Cardiac death was observed in 20 patients, and 1 patient died a non-cardiac death. Of 20 cardiac deaths, 10 patients died an arrhythmic death and 10 patients died due to pump failure. Nine patients were implanted with a prophylactic ICD, and 10 patients were implanted with a CRT at study entry.
| Study population and clinical outcome
The ICD therapy was unable to stop an electrical storm in 4 patients, and those patients died an AD. Reasons for not implanting an ICD during later follow-up in a patient with LVEF ≤ 30% were patients' refusal or the treatment policy of the attending physician. In addition, 2 ICD patients experienced an RCA. Overall, our primary endpoint was observed in 12 patients (10 AD and 2 RCA). Half of the patients with AD/RCA had a LVEF > 30%, and those patients were equally distributed in subgroups LVEF 31%-40% and 41%-50%
( Table 1 ). Two-thirds of patients who died during the follow-up (secondary end-point) had LVEF ≤ 30% and just over 50% had NYHA III functional class. None of the patients with NYHA I functional class died or had an RCA during the follow-up (Table 1 ).
| Biomarkers and arrhythmic death
In univariate Cox regression analysis, circulating GDF-15 was a strong predictor of AD/RCA during the median follow-up of 7.03 years with a crude HR per increase of 1-SD of 2.1 (95% CI:
1.1-4.3; P = .031; Table 2 ). GDF-15 remained a significant predictor of AD/RCA after adjustment for LVEF (adjusted HR = 2.2; 95% CI:
1.1-4.5; P = .028; Table 2 ). The area under the curve (AUC, Harrell's C-statistic) to predict AD/RCA increased from 0.68 (95% CI: 0.55-0.81) for age, sex and LVEF to 0.76 (95% CI: 0.64-0.88; P = .034; Table 3 ) when GDF-15 was added to a model. Figure 1A depicts survival curves for time to AD/RCA, accounting for deaths of other causes as competing events, stratified to baseline GDF-15 levels above or below the median of 884 pg/mL. There was no association of GDF-15 above the median and time to AD/RCA (Gray's test: P = .179). In contrast to GDF-15, increased sST2 levels did not predict AD/RCA (HR = 1.5; 95% CI: 0.8-2.8; P = .191; Table 2 ). As demonstrated in Figure 1B , there was also no association between baseline sST2 levels above the median and time to AD/RCA during the follow-up (Gray's test: P = .821).
| Biomarkers and all-cause mortality
Both GDF-15 and sST2 predicted all-cause mortality in univariate Cox regression models (HR = 3.1; 95% CI: 1.9-5.1; P < .001 vs HR = 2.2; 95% CI: 1.4-3.3; P < .001; Table 2 ). Figure 2A ,B show corresponding Kaplan-Maier survival curves of groups stratified according to baseline levels of GDF-15 and sST2 above or below the median of 884 pg/mL and 19 ng/mL, respectively (log-rank test: P = .002 and P = .015).
In a multivariable Cox regression model, including LVEF and NYHA functional class, GDF-15 was an independent predictor for all-cause mortality with an adjusted HR of 2.4 (95% CI: 1.4-4.2; P = .003; Table 2 ). In the same model, sST2 independently predicted all-cause mortality (adjusted HR = 1.6; 95% CI: 1.05-2.7; P = .030; Table 2 ).
When both GDF-15 and sST2 were included in a model with LVEF and NYHA functional class, only GDF-15 remained a significant predictor for all-cause mortality in patients with non-ischaemic DCM (adjusted HR = 2.2; 95% CI: 1.05-5.2; P = .038 vs HR = 1.04; 95% CI: 0.6-1.9; P = .907; Table 2 ). Furthermore, GDF-15 independently predicted all-cause mortality after adjustment for NT-proBNP and uric acid (adjusted HR = 1.8; 95% CI: 1.1-3.0; P = .025 and adjusted HR = 2.6; 95% CI: 1.6-4.2; P < .001, respectively; Table 2 ). In contrast, sST2 independently predicted all-cause mortality after adjustment for uric acid (adjusted HR=1.8; 95% CI: 1.1-2.8; P = .011; Table 2 ), but not after adjustment for NT-proBNP (adjusted HR=1.5;
95% CI: 0.9-2.3; P = .114; Table 2 ). Adding GDF-15 to a model with age, sex and LVEF improved AUC for prediction of all-cause mortality from 0.72 (95% CI: 0.59-0.84) to 0.79 (95% CI: 0.68-0.91; P = .052; Table 3 ). There was no improvement of AUC when sST2 was added to the same model (AUC 0.76; 95% CI: 0.65-0.87).
| DISCUSSION
We compared the prognostic value of GDF-15 and sST2 for prediction of fatal ventricular arrhythmias and all-cause mortality in patients with non-ischaemic DCM. In contrast to sST2, GDF-15 was found to be an independent predictor of documented arrhythmic death or RCA in patients with non-ischaemic DCM. GDF-15 provided incremental prognostic information to LVEF in risk stratification for documented arrhythmic death or RCA. Furthermore, both GDF-15 and sST2 were strongly associated with all-cause mortality, and this association was independent from clinical risk factors such as LVEF and NYHA functional class. Finally, head-to-head comparison demonstrated that GDF-15 was superior to sST2 in prediction of all-cause mortality in non-ischaemic DCM.
Prophylactic ICD implantation in patients with non-ischaemic DCM did not improve long-term survival in a recently published DANISH trial. 8 However, almost twice as much patients died a sudden cardiac death in a control group as compared to the ICD group. 8 These recent findings highlight the importance to define an improved risk stratification strategy for prophylactic ICD implantation in patients with non-ischaemic DCM.
To best of our knowledge, this is the first study with a head-tohead comparison of the prognostic value of GDF-15 and sST2 for prediction of long-term arrhythmic and all-cause mortality exclusively in patients with non-ischaemic DCM. So far, only few studies have investigated GDF-15 and sST2 in patients with non-ischaemic DCM. 21, 37 Although an association of both GDF-15 and sST2 with Because of different aetiologies of the disease leading to different risks of AD, 5, 8 it is of paramount importance to separately investigate ischaemic and non-ischaemic heart failure patients. In addition, previous studies used sudden cardiac death as an end-point, which
is not always equivalent to fatal ventricular arrhythmia. Therefore, our primary end-point was documented arrhythmic death or RCA (AD/RCA).
The present study demonstrates that a two-fold increase of GDF-15 was associated with a two-fold higher risk of AD/RCA, whereas no association was observed for sST2. Currently, LVEF is the gold standard for risk stratification of heart failure patients, and
severe LVEF reduction is an indication for prophylactic ICD implantation. 3, 4 However, LVEF reflects the global systolic function of the heart, and does not necessarily correlate with pathological changes in myocardium facilitating VT. In the underlying study, GDF- 46, 47 In addition, the study by Ahmad et al demonstrated that sST2 was a better prognostic marker for heart failure than for sudden cardiac death. 37 Thus, the prognostic value of sST2 might be its ability to predict heart failure, rather than fatal VTs in patients with non-ischaemic DCM. 46, 48 In agreement with previously published data, sST2 independently predicted all-cause mortality in the present study. Similarly, GDF-15 levels were also independently associated with all-cause mortality, as was shown previously. 14, 17 Uric acid was previously shown to be a powerful prognostic marker in patients with chronic heart failure, and uric acid levels were associated with GDF-15. 14, 49 In the present study, both GDF-15 and sST2 were superior to uric acid for prediction of all-cause mortality. In contrast to sST2, GDF-15 predicted allcause mortality independently of NT-proBNP. These results are in agreement with previous studies. 14, 21 Finally, in a model including sST2 and GDF-15, only latter remained significantly associated with all-cause mortality in non-ischaemic DCM patients. These results suggest that in non-ischaemic heart failure, GDF-15 might be superior to sST2 in predicting all-cause mortality. 
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